Use of NSAIDs in treating patients with arthritis

Arthritis Research and Therapy

Volumn 15, Issue SUPPL 3, 2013, Pages

  Crofford, Leslie J ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; DICLOFENAC; DICLOFENAC PLUS MISOPROSTOL; DICLOFENAC POTASSIUM; DIFLUNISAL; ESOMEPRAZOLE PLUS NAPROXEN; ETODOLAC; ETORICOXIB; FAMOTIDINE PLUS IBUPROFEN; FENOPROFEN CALCIUM; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; MECLOFENAMATE SODIUM; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PYRAZOLONE; SALSALATE; SULINDAC; TOLMETIN; PROSTAGLANDIN;

ACUTE KIDNEY FAILURE; AGING; ASEPTIC MENINGITIS; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COLITIS; CONFUSION; CYTOPENIA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; EOSINOPHILIA; ESOPHAGITIS; GENETIC VARIABILITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INTERSTITIAL NEPHRITIS; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE ACIDOSIS; NONHUMAN; OSTEOARTHRITIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PERIPHERAL EDEMA; PLASMA HALF LIFE; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; SODIUM RETENTION; SUSTAINED DRUG RELEASE; ULCER PERFORATION; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; ARTHRITIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KIDNEY DISEASE; LIVER DISEASE; METABOLISM; PAIN; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; BIOSYNTHETIC PATHWAYS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; LIVER DISEASES; PAIN; PROSTAGLANDINS; RISK FACTORS;

EID: 84880732103     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4174     Document Type: Review

References (54)

1. Crofford L. Prostanoid biology and its therapeutic targeting. Kelley's Textbook of Rheumatology 2013, 871-893. Philadelphia: Saunders, Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, 9.
2. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LBA. Basic biology and clinical application of specific COX-2 inhibitors. Arthritis Rheum 2000, 43:4-13. 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V, 10643694.
3. Lanas A. Nonsteridal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am J Med Sci 2009, 338:96-106. 10.1097/MAJ.0b013e3181ad8cd3, 19680014.
4. Patrono C, Patrignani P, Garcia-Rodrigues LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2002, 108:7-13.
5. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez L. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010, 62:1592-1601. 10.1002/art.27412, 20178131.
6. Capone ML, Tacconelli S, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol Rep 2010, 62:530-535.
7. Hinz B, Brune K. A ntipyretic analgesics: nonsteroidal anti-inflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. Handb Exp Pharmacol 2007, 177:65-93.
8. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 2000, 69:145-182. 10.1146/annurev.biochem.69.1.145, 10966456.
9. Simmons DL, Bottin g RM, Hla T. The biology of prostaglandin synthesis and inhibition. Pharmacol Revs 2004, 56:387-437.
10. Llorens O, Perez JJ, Palomar A, Mauleon D. Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model 2002, 20:359-371. 10.1016/S1093-3263(01)00135-8, 11885959.
11. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433-442. 10.1056/NEJM200108093450607, 11496855.
12. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007, 82:85-94. 10.1016/j.prostaglandins.2006.05.019, 17164136.
13. Kurumbail RA, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by antiinfl ammatory agents. Nature 1996, 384:644-648. 10.1038/384644a0, 8967954.
14. Barkin RL. Topica l nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome. Am J Ther 2012,
15. Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010, 50:50-61. 10.1177/0091270009336234, 19841157.
16. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2012, 9:CD007400.
17. Lanza PL, Chan FK L, Quigley EMM. Guidelines for prevention of NSAIDrelated ulcer complications. Am J Gastroenterol 2009, 104:728-738. 10.1038/ajg.2009.115, 19240698.
18. Ashworth NL, Peloso PM, Muhanjarine N, Stang M. Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, arthrotec, diclofenac, and naproxen in a population based cohort study. J Rheumatol 2005, 32:2212-2217.
19. Gigante A, Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/ omeprazole. Clin Drug Investig 2012, 32:221-233. 10.2165/11596670-000000000-00000, 22350497.
20. Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010, 32:401-413. 10.1111/j.1365-2036.2010.04378.x, 20497139.
21. Bello AE. DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug. Ther Adv Musculoskelet Dis 2012, 4:327-339. 10.1177/1759720X12444710, 3458616, 23024710.
22. Keeble JE, Moore P K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal atni-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002, 137:295-310. 10.1038/sj.bjp.0704876, 1573498, 12237248.
23. Hochberg MC. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum 2002, 32:4-14. 10.1053/sarh.2002.37215, 12528069.
24. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001, 41:299-332. 10.1016/S0168-0102(01)00289-9, 11755218.
25. Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostglandin E2 is mediated by inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001, 21:5847-5853.
26. Kunori S, Matsumura S, Okuda-Ashtaka E, Katano T, Audoly LP, Urade Y, Ito S. A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord. Glia 2011, 59:208-218. 10.1002/glia.21090, 21125641.
27. Ballou LR, Botting RM, Goorha S, Zhang J, R VJ. Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci USA 2000, 97:10272-10276. 10.1073/pnas.180319297, 27868, 10954756.
28. Trelle S, Reichenback S, Wandel S, Hildebrand P, Tschannen B, Billiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011, 342:c7086. 10.1136/bmj.c7086, 3019238, 21224324.
29. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002, 32:33-42. 10.1053/sarh.2002.37216, 12528072.
30. FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest 2002, 110:33-34. 151038, 12093885.
31. Harris RC, Breyer MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 2006, 1:236-245. 10.2215/CJN.00890805, 17699212.
32. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2 selective inhibitors. Am J Nephrol 2001, 21:1-15. 10.1159/000046212, 11275626.
33. Gurwitz JH, Avorn J, Bonh RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994, 272:781-786. 10.1001/jama.1994.03520100043031, 8078142.
34. Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002, 40:604-608. 10.1161/01.HYP.0000035856.77718.DA, 12411450.
35. Akhund L, Quinet R J, Ishaq S. Celecoxib-related renal papillary necrosis. Arch Intern Med 2003, 163:114-115. 10.1001/archinte.163.1.114, 12523925.
36. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder C-G, Blot WJ, McLaughlin JK, Zack MM, Nyrén O. Acetaminophen, aspirin, and chronic renal failure: a nationwide case-control study in Sweden. N Engl J Med 2001, 345:1801-1808. 10.1056/NEJMoa010323, 11752356.
37. Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziono JM. Analgesic use and renal function in men. JAMA 2001, 286:315-321. 10.1001/jama.286.3.315, 11466097.
38. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: a cumulative metaanalysis. Lancet 2004, 364:2021-2029. 10.1016/S0140-6736(04)17514-4, 15582059.
39. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general populations. J Am Coll Cardiol 2008, 52:1628-1636. 10.1016/j.jacc.2008.08.041, 18992652.
40. FitzGerald GA. Coxibs and cardiov ascular disease. N Engl J Med 2004, 351:1709-1711. 10.1056/NEJMp048288, 15470192.
41. Harirforoosh S, Aghazadeh-Habashi A, Jamali F. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin Exp Pharmacol Physiol 2006, 33:917-924. 10.1111/j.1440-1681.2006.04464.x, 17002668.
42. Mackenzie IS, Coughtrie MW, MacDonald TM, Wei L. Antiplatelet drug interactions. J Intern Med 2010, 268:516-529. 10.1111/j.1365-2796.2010.02299.x, 21073556.
43. Friedewald VE, Bennett JS, Christo JP, Pool JL, Scheiman J, Simon LS, Strand V, White WB, Williams GW, Roberts WC. AJC Editor's Consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. Am J Cardiol 2010, 106:873-884. 10.1016/j.amjcard.2010.04.006, 20816131.
44. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E, Cross Trial Safety Assessment Group Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial sarety analysis. Circulation 2008, 117:2104-2113. 10.1161/CIRCULATIONAHA.108.764530, 2965408, 18378608, Cross Trial Safety Assessment Group.
45. Feenstra J, Heerdink ER, Grobbee DE, Stricker BR. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with replapsing heart failure: the Rotterdam Study. Arch Intern Med 2002, 162:265-270. 10.1001/archinte.162.3.265, 11822918.
46. Page J, Henry D. Consumption of N SAIDs and the development of congestive heart failure in elderly patients: an under-recognized public health problem. Arch Intern Med 2000, 160:777-784. 10.1001/archinte.160.6.777, 10737277.
47. Brater DC. Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs. Am J Med 1986, 80:62.
48. Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of nonsteroidal anti-inflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 2012, 90:62-73. 10.3899/jrheum.120345, 22942332.
49. White WB. Defining the problem of treating the patient with hypertension and arthritis pain. Am J Med 2009, 122(5 Suppl):S3-S9.
50. Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal anti-inflammatory drugs: review of the literature. Pharmacotherapy 2006, 26:1307-1313. 10.1592/phco.26.9.1307, 16945053.
51. Hauber AB, Arden NK, Mohamed AF, Johnson FR, Peloso PM, Watson DJ, Mavros P, Gammaitoni A, Sen SS, Taylor SD. A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthritis Cartilage 2013, 21:289-297. 10.1016/j.joca.2012.11.007, 23182815.
52. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000, 43:378-385. 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2, 10693878.
53. Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, Luta G, Callahan LF, Wang X, Schwartz T, Abramson SB, Caldwell JR, Harrell RA, Kremer JM, Lautzenheiser RL, Markenson JA, Schnitzer TJ, Weaver A, Cummins P, Wilson A, Morant S, Fort J. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587-1598. 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X, 11465710.
54. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499. 10.1016/j.joca.2010.01.013, 20170770.